Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purported market share. However, beginning on April 25, 2024, DexCom made its first in a series of public corrective disclosures announcing that the company's growth and business prospects were far lower than it had previously claimed. By the time the company made its final corrective disclosure on July 25, 2024, the price of DexCom's shares had plummeted by over 40.6%.
Current stockholders who held their DexCom stock before April 28, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights in this matter. You can click or copy and paste the following link to join this investigation: https://www.johnsonfistel.com/investigations/dexcom-inc-2
About Johnson Fistel, PLLP:
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Inside Dexcom's strategy to stay ahead in the $13.6bn CGM market
Dexcom stands as the US leader in the continuous glucose monitoring (CGM) space as it continues to innovate and diversify its product lines to simplify blood glucose monitoring for type 2 diabetes (T2D) patients. The global diabetes population is projected to hit 643 million by 2030, as per the International Diabetes Federation (IDF). According to GlobalData analysis, the global CGM market is growing at a CAGR of 8.62% and is projected to reach a valuation of $13.6bn by 2034, up from $5.9bn in 2024. In the US, Dexcom held an estimated 74% share of the CGM market in 2024. Other major players in the CGM space include Abbott with its FreeStyle Libre CGM system and Medtronic with its MiniMed CGM. A strong constituent of Dexcom's continued US market lead is in the diversification of its CGM technology, with smartphone integrations for its G7 CGM system, the recent roll out of over-the-counter (OTC) CGM Stelo, claimed to be the first glucose biosensor available in the US without a prescription, and recent collaborations that aim to tap into the booming wellness wearables market. According to a 2023 report from GlobalData, the wearable technology market is forecast to grow from $99.5bn in 2022 to $290.6bn in 2030. In 2024, Dexcom invested $75m into ŌURA, forging a partnership that makes Dexcom the only CGM compatible with the Finnish company's Oura smart ring. The Oura smart ring, which measures wellness metrics such as sleep, stress, and cardiovascular data, and CGM data, has so far sold around 2.5 million units worldwide, following Dexcom's investment. In addition, Dexcom leads in native integration with Apple Watch, standing as the only company currently offering direct-to-watch connectivity with its G7 sensor since integrating with the wearable in June 2024. Dexcom recently announced Q2 2025 revenues exceeding $1.1bn, a 15% uplift on Q2 2024. The company also revealed that from 1 January 2026, Dexcom's chief operating officer, Jake Leach, will take over from outgoing CEO Kevin Sayer as Dexcom's new CEO. In Dexcom's 30 July earnings call, Sayer said: 'Today's announcement of Jake's transition to the role of CEO reflects the Board's comprehensive succession planning and their confidence in Jake's leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom's momentum and extend the company's growth well into the future.' Medical Device Network sat down with Sayer to learn more about how the company will maintain its market position and drive innovation in the CGM space in the future. This interview has been edited for length and clarity. Ross Law (RL): How do you expect Dexcom's role to evolve over the next 3-5 years as the CGM space continues to grow more competitive? Kevin Sayer (KS): I think we'll continue to be a leader. We have grown dramatically over the past several years, and we have no intention of slowing down. Part of maintaining our market-leading position will involve continuing to enhance our technology. We've always been a company built on product excellence, and that will continue. As we move forward, we've learned that creating an optimal customer experience is very important. Now that our CGMs are mobile-based, we continue to look at how we can make life even better for diabetes patients. Nutrition is important to people with diabetes and those without. With this in mind, we have now added an AI provision where Dexcom G7 users can more easily log their nutrient intake by photographing their food with their smartphone. This is just one area we will continue to elaborate on to further improve the patient experience. As competition goes, there's more technology coming, but at the same time, we've invested billions of dollars in scaling our business. Scaling a CGM is not a simple task. We've built out a factory in Arizona and now have a factory in Malaysia that supplies more products, and we are working on finishing a factory in Ireland that we anticipate being at full scale by 2027. The scale of a CGM business to meet patient needs is really important, and I think that's a strong advantage for our team, and one we've built with our financial muscle and resources combined with our financial success in the marketplace. RL: What are Dexcom's current geographical focuses? KS: We are continuing to invest in the US, particularly as we have obtained much more coverage in the area of T2D for those not on insulin. We have a great market expansion opportunity in the US, and we've been able to obtain coverage from the three largest pharmacy benefit managers in the US for people with T2D who are not on insulin already. As for the rest of the world, the countries within Europe represent our next largest market, and we're continuing to focus on markets, particularly those where CGM is reimbursed. In the UK, we have Dexcom One Plus, which is lower cost, and while it doesn't connect with our automated insulin delivery system partners, it still provides patients with an optimal experience for managing their diabetes and gets reimbursed at a lower rate than our G7 product. We look at every country and the coverage available. There are other places where we've adopted an online strategy, originally, knowing there's no coverage, but if we go online and offer a cash paid product to individuals, they'll buy it. After a very long period of time, after people start buying the device online with their own money, the reimbursement authorities often come and cover the product. RL: What is your roadmap for Dexcom G7 and beyond? KS: Our next G7 product launch will be in the US, and we'll extend the device's lifespan out to 15 days. And that will be very important. Patients want it, and they don't want to change their sensor for this if they don't have to. Initially, for adults, the 15-day product will see a limited launch in the US in Q3, with a complete rollout expected by Q4. As mentioned, with respect to G7, we are continuing to enhance the app with the aforementioned AI function, and we plan to add more analytics to it over time. One thing we've done to improve the experience for a different group of customers are physicians. We're working hard on electronic healthcare record (EHR) integration. We have more than 100 clinics in the US in the process of or having integrating Dexcom CGM data into EPIC's EHR systems. And that'll be very important in the EU going forward, as many of the countries have talked about integrating sensor data with medical records. We have our Stelo device in the US, and we'll start rolling that out internationally in future periods. We've had great success with Stelo in the US so far, and we'll continue to expand that product offering, and again, add features and integrate more data to give people a better picture of their overall health. RL: Are there any plans to expand CGM into other indications such as health, wellness and metabolic health? KS: While we have not labelled anything for these indications, there is a migration towards them. We have API Interfaces that we share with several partners, and several of those apps that work with Stelo or G7 are, in fact, geared towards wellness and putting people in better overall metabolic health. We announced a recent partnership with ŌURA, for example, and Oura users are using Stelo and that Stelo data is displayed in the Oura ring app, along with Oura ring data, and those users will have their own insights as to what they think is most important concerning glucose data and other wellness metrics provided by Oura ring. RL: As a medtech CEO in this turbulent modern healthcare landscape, what keeps you up at night? KS: That's a good question, and those things have changed over the years, given that when I started with Dexcom, our revenue the previous year was $40m, and you can see where we are at now (Dexcom achieved revenues of around $4bn in 2024). One of the things I wake up and think about sometimes is that I want to make sure that, as a leader of this company, we don't miss the opportunity to change the lives of as many people as we can by not executing on our operations and having enough infrastructure in place to do the things we need to do. I think about that, and I think we've done a good job of scaling and building the business out to meet those requirements. We have to make sure we build a business that enables us to make our products more accessible to more people, to get them the clinical benefits of CGM, and at the same time, run a profitable business that generates proper returns to our shareholders. We've balanced this well over the years and will continue to do so. "Inside Dexcom's strategy to stay ahead in the $13.6bn CGM market" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
06-08-2025
- Business Wire
Johnson Fistel Investigates Marex Group Following Damaging Short Seller Allegations
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Marex Group plc (NASDAQ: MRX) regarding possible violations of federal securities laws. Investors who purchased Marex Group securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the Company and its executives. Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Marex Group plc (NASDAQ: MRX) regarding possible violations of federal securities laws. What if I purchased Marex Group securities? If you incurred significant losses and want to determine if you are eligible to participate in the potential class action or to seek a recovery of your losses, follow the link provided: For more information, contact James Baker at (619) 814-4471, jimb@ or fjohnson@ On August 5, 2025, NINGI Research published a short report containing multiple allegations, including the statement that, 'Marex has engaged in a multi-year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure. We have uncovered evidence suggesting Marex is a financial house of cards, with a balance sheet riddled with holes and financials that we believe are unreliable.' About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, PLLP can help you recover your losses. For more information about the firm and its attorneys, please visit Achievements: In 2024, Johnson Fistel was honored to be ranked in the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. This recognition underscores our effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where we served as lead or co-lead counsel. This notable accomplishment marks the eighth occasion our firm has been recognized as a top plaintiffs' securities law firm in the United States, as determined by the total dollar value of final recoveries. Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
CNBC
05-08-2025
- CNBC
Dexcom's Arizona facility can service good portion of U.S. business, says CEO
CNBC's "The Exchange" team discusses the potential of tariffs on pharmaceuticals, U.S. manufacturing and more with Dexcom CEO and chairman Kevin Sayer.
